Employing clinically optimized thresholds, survival analysis confirmed that a PLR ≥140, SII ≥520, and CD4+/CD8+ T cell ratio <1.6 could significantly predict the 2-year CRPC risk.<h4>Conclusion</h4>The PLR, SII, CD4+/CD8+ T cell ratio, and T4 tumor stage are independent risk factors for CRPC progression within 2 years of endocrine therapy. This evidence concerns the gene CD4 and neoplasm.